Morepen Laboratories profit and loss

Latest FY26

Revenue: ₹1,806cr−0.3% on FY25
EBITDA: ₹126cr−27.8% on FY25
Net profit: ₹94.9cr−19.6% on FY25
EPS: ₹1.73−21.4% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	2,286	1,806	1,812	1,690	1,418	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	26.1	21.3	18.4	14.0	6.1
	2,312	1,827	1,830	1,704	1,424
	1,325	1,043	999	883	781
	50.0	82.5	207	177	158
	−70.7	−2.1	−47.1	2.1	16.5
	263	233	209	181	155
	18.2	16.4	8.3	3.7	2.0
	34.5	36.4	29.0	33.5	27.9
	442	324	269	288	228
	2,062	1,733	1,675	1,569	1,368
	276	126	174	159	79.5
	242	89.2	145	125	51.6
Profit
	250	94.1	155	135	55.8
	0.0	25.8	0.0	0.0	0.0
	250	120	155	135	55.8
	46.4	15.8	32.4	39.2	16.9
	15.0	8.5	4.7	−0.4	0.2
	61.3	24.3	37.1	38.8	17.1
	0.1	−0.8	0.0	−0.5	−0.0
	189	94.9	118	96.2	38.7
	188	95.6	118	96.6	38.7
	7.2	6.2	0.3	−1.8	−1.5
	196	101	118	94.3	37.2
	—	94.9	118	96.2	—
Per share
	₹3.43	₹1.73	₹2.20	₹1.88	₹0.77
	₹3.43	₹1.73	₹2.20	₹1.88	₹0.77
Revenue detail — as filed
	—	0.0	0.0	−0.5	−0.0
Other comprehensive income — detail
	7.2	6.2	0.3	—	—
	7.2	6.2	0.3	−2.8	−2.0
	0.2	0.0	0.1	—	—
	—	—	—	−0.7	−0.5
	—	−0.0	0.1	0.2	—
	—	—	118	—	—
Per share — as-filed variants
	₹3.43	₹1.73	₹2.20	₹1.88	₹0.77
	₹3.43	₹1.73	₹2.20	₹1.88	₹0.77
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	981	682	652	628	462
	42.9%	37.8%	36.0%	37.2%	32.6%
Adjusted (ex-exceptional items) — derived
	250	94.1	155	135	55.8
	0.0	25.8	0.0	0.0	0.0
	189	74.3	118	96.2	38.7
	₹3.43	₹1.35	₹2.20	₹1.88	₹0.77

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MOREPENLAB₹125.58

Morepen Laboratories Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersIOLCP INNOVACAP FDC ORCHPHARMA SENORES SANOFI GUJTHEM RPGLIFEMcap ₹6,881 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	1,417.5	1,690.4	1,811.6	1,805.7	2,285.5
Other Income	6.1	14.0	18.4	21.3	26.1
Total Income	1,423.7	1,704.4	1,829.9	1,827.0	2,311.6
Expenses
+ Cost of Materials Consumed	781.4	883.3	999.2	1,043.1	1,325.0
+ Purchases of Stock-in-Trade	157.9	177.0	207.2	82.5	50.0
+ Changes in Inventories	16.5	2.1	-47.1	-2.1	-70.7
+ Employee Benefit Expense	154.7	181.5	208.9	232.7	263.0
+ Finance Costs	2.0	3.7	8.3	16.4	18.2
+ Depreciation & Amortisation	27.9	33.5	29.0	36.4	34.5
+ Other Expenses	227.6	287.9	269.3	323.9	441.7
Total Expenses	1,367.9	1,569.0	1,674.8	1,732.9	2,061.9
EBITDA	79.5	158.6	174.1	125.6	276.4
EBIT	51.6	125.2	145.1	89.2	241.9
Profit
PBT before Exceptional Items	55.8	135.4	155.1	94.1	249.8
+ Exceptional Items	0.0	0.0	0.0	25.8	0.0
Pretax Income	55.8	135.4	155.1	119.9	249.8
+ Current Tax	16.9	39.2	32.4	15.8	46.4
+ Deferred Tax	0.2	-0.4	4.7	8.5	15.0
Tax Expense	17.1	38.8	37.1	24.3	61.3
+ Share of Associates & JVs	-0.0	-0.5	0.0	-0.8	0.1
Net Income	38.7	96.2	118.0	94.9	188.5
+ Net Income — Continuing Ops	38.7	96.6	118.0	95.6	188.4
+ Other Comprehensive Income	-1.5	-1.8	0.3	6.2	7.2
Total Comprehensive Income	37.2	94.3	118.3	101.1	195.8
Net Income to Common	—	96.2	118.0	94.9	—
Per Share
Basic EPS	0.77	1.88	2.20	1.73	3.43
Diluted EPS	0.77	1.88	2.20	1.73	3.43
Revenue Detail — as filed
+ Share of P&L — Partnership Firms / LLPs	-0.0	-0.5	0.0	0.0	—
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	0.3	6.2	7.2
+ Items NOT to be Reclassified to P&L	-2.0	-2.8	0.3	6.2	7.2
+ Tax on Items NOT to be Reclassified	—	—	0.1	0.0	0.2
+ Tax on Items NOT to be Reclassified — alt tag	-0.5	-0.7	—	—	—
+ Items to be Reclassified to P&L	—	0.2	0.1	-0.0	—
Comprehensive Income — Owners of Parent	—	—	118.0	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	0.77	1.88	2.20	1.73	3.43
Diluted EPS — Continuing Operations	0.77	1.88	2.20	1.73	3.43
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	461.8	628.0	652.3	682.3	981.1
Gross Margin %	32.58	37.15	36.01	37.78	42.93
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	55.8	135.4	155.1	94.1	249.8
− Exceptional Items (reconciliation)	0.0	0.0	0.0	25.8	0.0
Net Income Adj (tax-effected)	38.7	96.2	118.0	74.3	188.5
EPS Adj	0.77	1.88	2.20	1.35	3.43
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	102.2	102.2	109.6	109.6	109.6

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.